Roche’s Enicepatide Shows Superior Diabetes Control vs. Lilly’s Retatrutide in Phase 2 Trial

Key points

• Enicepatide, acquired via Roche’s $2.7 billion Carmot Therapeutics deal, achieved a 2.65% HbA1c reduction at 48 weeks, outperforming Lilly’s retatrutide (1.94%) and Ozempic (1.6%) at earlier timepoints.
• The drug demonstrated 15.5% mean weight loss at 48 weeks without a plateau, matching Lilly’s retatrutide performance at 40 weeks and suggesting potential for deeper loss in longer trials.
• Roche is advancing a broad phase 3 program, including global obesity trials and upcoming glycemic control and cardiovascular studies, aiming to challenge Lilly’s market position.
• Safety profiles remained consistent with the class, with 2% discontinuation due to adverse events, mostly mild gastrointestinal issues, compared to 0% in the placebo group.

Background

GLP-1 therapies have expanded beyond weight loss and diabetes into cardiovascular, kidney, and liver health, as noted in prior coverage. Eli Lilly recently strengthened Mounjaro’s diabetes label to counter insurer pullbacks on obesity coverage. Roche’s entry into this space adds a new competitor to a market where Lilly currently dominates high-efficacy weight loss agents.

Why it matters

Roche’s data suggests enicepatide could disrupt the GLP-1 market by offering superior glycemic control and sustained weight loss, potentially challenging Lilly’s dominance and influencing future insurance coverage decisions for diabetes and obesity treatments.

What to watch

Roche plans to launch phase 3 glycemic control and cardiovascular outcomes trials in the first half of 2027, while continuing global obesity trials. Detailed safety data and long-term efficacy results will be critical for regulatory and market positioning.